A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated with Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age - NIL

开始日期2026-03-12

申办/合作机构

Intra-Cellular Therapies, Inc.

[+1]

NCT07369115

/ Not yet recruiting临床4期IIT

Intra-Cellular Therapies, Inc. / "A Randomized, Double-blind, Placebo-controlled, Single Site Study to Evaluate the Efficacy of Lumateperone for the Treatment of Major Depressive Disorder (MDD) and Early Life Trauma in Adult Patients Aged 21 to 70 Years

The purpose of this clinical research study is to understand how effective and safe an investigational study drug called lumateperone is and whether it works to reduce the severity of depressive symptoms in adults with Major Depressive Disorder (MDD) and early life trauma. The main questions it aims to answer are:
Aim 1: To assess the efficacy of lumateperone 42 mg administered once daily compared with placebo in the treatment of patients with Major Depressive Disorder and early life abuse.
Aim 2: To assess neurocircuitry encoding of threat and reward learning as predictors of lumateperone response and as mechanisms of treatment action, and assess the change from pre-dose to post-dose of task-evoked brain activation.

开始日期2026-02-01

申办/合作机构

The University of Texas at Austin

CTR20254391

/ Active, not recruitingN/A

甲苯磺酸卢美哌隆胶囊在空腹条件下的人体生物等效性研究

主要研究目的研究空腹状态下单次口服受试制剂甲苯磺酸卢美哌隆胶囊与参比制剂甲苯磺酸卢美哌隆胶囊（CAPLYTA®）在健康成年受试者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的研究受试制剂甲苯磺酸卢美哌隆胶囊和参比制剂“CAPLYTA®”在健康受试者中的安全性。

开始日期2026-01-12

申办/合作机构

齐鲁制药有限公司

100 项与甲苯磺酸卢美哌隆相关的临床结果

登录后查看更多信息

100 项与甲苯磺酸卢美哌隆相关的转化医学

登录后查看更多信息

100 项与甲苯磺酸卢美哌隆相关的专利（医药）

登录后查看更多信息

116

项与甲苯磺酸卢美哌隆相关的文献（医药）

2026-03-01·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study

Article

作者: Kozauer, Susan G. ; Tohen, Mauricio ; Davis, Robert E. ; Mates, Sharon ; Durgam, Suresh ; Chen, Changzheng

This 6-month open-label extension (OLE) period of a Phase 3 placebo-controlled study (NCT02600494) examined the safety of lumateperone in patients with bipolar I or bipolar II depression. Eligible patients completing the placebo-controlled period received lumateperone 42 mg once daily up to 175 days. The primary endpoint was safety and tolerability, assessed by adverse events (AEs) and clinical laboratory evaluations analyzed by imputing missing data using a last observation carried forward approach. The secondary endpoint was efficacy measured by Montgomery-Åsberg Depression Rating Scale (MADRS) total and Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) scores. Of 127 patients in the OLE, 58.3% completed treatment, and 42.5% experienced a drug-related treatment-emergent AE (TEAE); the most common TEAEs were headache (20.5%), dry mouth (11.8%), dizziness (10.2%), and nausea (10.2%). The majority (92%) of TEAEs were of mild or moderate severity. There were no notable changes in extrapyramidal symptom scores, cardiometabolic parameters, or body morphology. MADRS total score (mean change, −8.9, nominal P < 0.0001), CGI-BP-S total score (−2.3, nominal P < 0.0001), and CGI-BP-S depression subscore (−1.3, nominal P < 0.0001) improved over time, from baseline to Day 175. Overall, 6-month lumateperone 42 mg was generally well tolerated, and depressive symptoms based on MADRS total score and CGI-BP-S improved over time.

2026-03-01·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial

Article

作者: Chen, Changzheng ; Kozauer, Susan G. ; Mates, Sharon ; Correll, Christoph U. ; Davis, Robert E. ; Lakkis, Hassan D. ; Durgam, Suresh ; Vanover, Kimberly E.

This Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of lumateperone to treat bipolar depression. Patients (18–75 years) with bipolar I or bipolar II disorder experiencing a major depressive episode were randomized 1:1:1 to 6-week lumateperone 28 mg ( n = 183), lumateperone 42 mg ( n = 185), or placebo ( n = 186). Primary and key secondary endpoints were change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total score and time to first sustained response (≥50% reduction from baseline in MADRS Total score), respectively. Safety assessments included adverse events, extrapyramidal symptoms (EPS), laboratory evaluations, and vital signs. Neither dose of lumateperone achieved significant improvement vs. placebo ( P > 0.05) in the primary endpoint (MADRS Total score, least squares mean difference vs. placebo: 28 mg, 0.9; 42 mg, −1.0) or in the key secondary endpoint (MADRS Total time to first sustained response hazard ratio vs. placebo: 28 mg, 1.00; 42 mg, 0.93), likely due to a high placebo response. Both lumateperone doses were well tolerated, with low EPS risk and minimal changes in weight, prolactin, and cardiometabolic or endocrine parameters. While study efficacy objectives were not met, both doses of lumateperone were generally safe and well tolerated in patients with bipolar depression.

2026-01-21·Central nervous system agents in medicinal chemistry

Clinical Effects of Recently Developed Antipsychotic Drugs in Schizophrenia

Article

作者: Coveñas, Rafael ; Werner, Felix-Martin

Introduction::

Schizophrenia and schizoaffective disorder are generally treated with second- generation antipsychotic drugs. These drugs are mostly dopaminergic (D2) and serotonergic (5-HT2A) antagonists. They sufficiently improve positive schizophrenia symptoms; however, they ameliorate negative symptoms and cognitive functions only to a limited extent.

Material and Methods::

We review novel antipsychotic drugs that exert partial agonism at dopaminergic and serotonergic receptors, such as cariprazine, brexpiprazole, and lumateperone. In addition, the mechanisms of action of non-dopaminergic antipsychotic drugs are described. Updated neural network models are used to explain the mechanisms of action of muscarinic (M4 and M1) receptor agonists (e.g., xanomeline combined with trospium) and trace-amine-associated receptor 1 (TAAR1) agonists (e.g., ulotaront). Phase 3 clinical trials of new third-generation antipsychotic drugs are also presented.

Results::

Novel antipsychotic drugs with partial agonism at D2 and D3 receptors improve positive and negative schizophrenia symptoms, as well as cognitive symptoms, more effectively than second- generation antipsychotic drugs. They are also well tolerated. M4 and M1 receptor agonists (i.e., xanomeline combined with trospium or emraclidine) and TAAR1 agonists (i.e., ulotaront) substantially improve negative schizophrenia symptoms and cognitive functions. These new nondopaminergic antipsychotic drugs better ameliorate negative symptoms and improve cognitive functions compared with second-generation antipsychotic drugs.

Discussion::

Results from phase 3 clinical studies indicate the clinical efficacy of new thirdgeneration antipsychotic drugs.

Conclusion::

Promising new antipsychotic drugs include cariprazine, brexpiprazole, lumateperone, ulotaront, and xanomeline combined with trospium. Phase 3 clinical studies have shown therapeutic effects superior to those achieved with second-generation antipsychotic drugs.

358

项与甲苯磺酸卢美哌隆相关的新闻（医药）

2026-02-22

·Darkness of moon

FDA 催化剂事件投资建议

2026年上半年美国FDA关键监管催化剂与全球生物制药深度投资策略报告宏观监管环境与产业周期演变进入2026年第一季度，全球生物技术和制药行业的监管环境与资本周期正在经历微妙而深刻的结构性转变。美国食品药品监督管理局（FDA）近期的政策动向表明，监管机构正在重新校准其审批标准。特别是近期引发行业广泛关注的“单一关键性试验（One Pivotal Trial）”政策倾向，标志着FDA在承认生物学和临床知识积累的基础上，越来越接受通过多源确证性证据来替代传统的第二次三期临床试验1。这一转变的底层逻辑在于加速创新疗法的上市，但其衍生影响是复杂的：一方面，它显著降低了罕见病和孤儿药开发商的资本支出和研发周期；另一方面，这也意味着FDA在做出审批决定时，将更加严苛地审查化学、制造和控制（CMC）数据以及长期的真实世界安全性随访。如果新药在上市后暴露安全隐患，监管机构的信誉将面临巨大考验1。与此同时，联邦层面的卫生机构领导层更迭正在为行业带来新的不确定性与机遇。Jay Bhattacharya博士被任命为疾病控制与预防中心（CDC）的代理主任，而卫生与公众服务部（HHS）则迎来了更为激进的管理层1。这种政治与科学交织的背景，导致FDA在某些关键疫苗和公共卫生产品的审批上表现出异乎寻常的审慎。在技术基础设施层面，人工智能（AI）与生物技术的深度融合正在跨越概念验证阶段。2026年被称为“AI驱动生物学（AI-powered biology）”的元年。包括亚马逊、Alphabet、微软在内的超大规模云计算服务商（Hyperscalers）计划在2026年投入近7000亿美元用于AI基础设施建设，较2025年翻倍3。此外，“星门计划（Project Stargate）”等战略投资为生成式药物设计、蛋白质结构预测以及细胞数字孪生提供了庞大的算力支持3。印度等新兴市场也在2025-2026经济调查中明确提出通过应用特定的小型AI模型来重塑医疗筛查和药物可及性5。在这种计算资源极大丰富的环境下，生物技术公司将试验错误周期从数年压缩至数周的愿景正在逐步实现6。然而，2026年的生物技术资本市场依然呈现出明显的“两极分化”态势。针对肥胖症（GLP-1受体激动剂）、阿尔茨海默病以及自免疫疾病的重磅炸弹级别药物，吸引了大量机构资金的抱团，推高了大型制药公司的估值倍数；而处于临床阶段且面临二元风险（Binary Risk）的中小型生物技术公司，其估值依然受到高利率环境尾部效应和融资成本的压制。在这一背景下，准确把握FDA的《处方药使用者付费法案》（PDUFA）目标行动日期、临床试验数据读出（Data Readout）以及咨询委员会（AdCom）会议，成为了构建生物医药投资组合、获取超额收益的核心驱动力。2026年上半年核心监管催化剂全景概览为了系统性地跟踪和评估即将到来的行业重大事件，以下结构化数据表总结了2026年第一季度至第三季度最具市场影响力的FDA催化剂事件及其基本参数。催化剂日期公司名称 (股票代码)药物名称 / 候选药物适应症事件类型预估影响与信心指数2026年2月20日Vanda Pharmaceuticals (VNDA)Bysanti (milsaperidone)双相I型障碍与精神分裂症PDUFA (已获批) 高影响 (8/10) 72026年2月25日Eton Pharmaceuticals (ETON)ET-600 (去氨加压素口服液)尿崩症 / AVP-DPDUFA 高影响 (8/10) 72026年2月28日Ascendis Pharma (ASND)TransCon CNP软骨发育不全PDUFA (延期后) 高影响 (9/10) 92026年2月28日BioMarin Pharmaceutical (BMRN)PALYNZIQ (sBLA)青少年苯丙酮尿症 (PKU)PDUFA 中度影响 (7/10) 102026年3月6日Lantheus Holdings (LNTH)Piflufolastat F 18 (新配方)转移性前列腺癌PET成像PDUFA 中度影响 (8/10) 112026年3月16日Aldeyra Therapeutics (ALDX)Reproxalap干眼症 (DED)PDUFA (延期后) 高二元风险 (9/10) 72026年3月28日Rocket Pharmaceuticals (RCKT)KRESLADI (RP-L102)严重白细胞黏附缺陷I型PDUFA 高影响 (9/10) 72026年4月10日Eli Lilly (LLY)Orforglipron肥胖症与体重管理PDUFA (延期后) 极高影响 (10/10) 122026年4月10日Replimune (REPL)RP1 (vusolimogene)抗PD-1失败的晚期黑色素瘤PDUFA 高影响 (9/10) 72026年4月30日Axsome Therapeutics (AXSM)AXS-05 (sNDA)阿尔茨海默病激越 (ADA)PDUFA 极高影响 (9/10) 112026年5月10日Argenx (ARGX)VYVGART (sBLA)血清阴性全身型重症肌无力PDUFA 高影响 (8/10) 112026年6月30日Viridian Therapeutics (VRDN)Veligrotug甲状腺眼病 (TED)PDUFA 高影响 (8/10) 16 近期已落地催化剂深度复盘：Vanda Pharmaceuticals (VNDA) 的里程碑突破在探讨未来的催化剂之前，对近期已落地的关键事件进行复盘，有助于锚定FDA当前的审批尺度和市场对精神类药物的估值逻辑。 2026年2月20日，FDA正式批准了Vanda Pharmaceuticals的新化学实体Bysanti（milsaperidone），用于治疗成人双相I型障碍（Bipolar I Disorder）的急性躁狂和混合发作，以及精神分裂症（Schizophrenia）8。这一决定恰好在其原定的PDUFA目标行动日期（2月21日）前夕做出，显示了FDA审评流程的按时推进9。从行业基本面来看，抗精神病药物市场近年来创新活跃但竞争异常激烈。Bysanti作为一种全新的化学实体，为那些对现有疗法产生耐受性或存在严重副作用的精神分裂症及双相情感障碍患者提供了关键的替代选择20。尽管该市场目前由百时美施贵宝（Bristol Myers Squibb）的Cobenfy和强生（Johnson & Johnson）的Caplyta等成熟产品占据主导地位，但精神疾病极高的异质性意味着任何具有差异化受体结合谱的新药都能获得可观的市场份额22。深度战略分析表明，Vanda成功消除了该管线的二元监管风险。公司预计将于2026年第三季度在美国市场正式推出Bysanti22。从投资逻辑而言，VNDA目前的估值重心将从“监管审批风险”完全转移至“商业化执行能力”与“定价策略”上。此次获批不仅提振了Vanda自身的市场地位，也向整个中枢神经系统（CNS）药物研发领域传递了积极的信号，特别是为即将迎来PDUFA日期的其他精神/神经类药物（如Axsome的AXS-05）奠定了有利的监管环境背景。2026年第一季度核心PDUFA事件深度解析第一季度的FDA日历集中了多个具有高度确定性的小型改良药物以及面临严峻审批考验的孤儿药/罕见病疗法。分析这些标的有助于在控制宏观回撤风险的同时捕捉个股阿尔法收益。Eton Pharmaceuticals (ETON) - ET-600 催化剂日期：2026年2月25日 (PDUFA)9适应症：中枢性尿崩症 / 精氨酸加压素缺乏症 (AVP-D) Eton Pharmaceuticals提交的ET-600（去氨加压素口服溶液）旨在为患有尿崩症及夜尿症的患者提供一种针对儿科和吞咽困难成人的液体口服治疗方案21。该药物的NDA已于2025年6月获得FDA的标准审查受理9。考虑到该药物是基于已广泛使用的活性成分去氨加压素（Desmopressin）的剂型改良（505(b)(2)途径），其面临的疗效和安全性审查风险极低。Eton目前正在积极推进上市前营销和启动库存生产，目标是在2026年第一季度内实现全面的商业化推出9。财务和市场潜力方面，分析师预计ET-600的商业化推进将推动Eton的收入结构升级。华尔街对ETON的共识评级为“适度买入”至“强力买入”，平均12个月目标价为29.67美元，较其近期约17.93美元的交易价格有超过65%的潜在上涨空间24。Craig Hallum和H.C. Wainwright的分析师分别给予了28.00美元和35.00美元的乐观目标价24。从投资角度看，ET-600的获批属于高确定性事件，市场已部分计价，但作为防守型标的，其后续销售放量带来的稳定现金流依然具备投资吸引力。Ascendis Pharma (ASND) - TransCon CNP 催化剂日期：2026年2月28日 (PDUFA)9适应症：儿童软骨发育不全 (Achondroplasia) TransCon CNP（navepegritide）是一种采用Ascendis专有瞬时连接技术开发的长效C型钠尿肽（CNP）前体药物。此前，由于FDA需要更多时间审查补充信息（通常涉及化学、制造和控制CMC数据），其PDUFA日期被延长了三个月至2026年2月28日9。基于ACcomplisH和ApproaCH三期临床试验的积极顶线数据及52周延长数据，该药物展示了显著的促骨骼生长疗效9。 TransCon CNP的获批将直接重塑软骨发育不全的治疗市场格局，直接挑战BioMarin旗下Voxzogo的垄断地位。长效制剂在儿科患者中能够大幅降低注射频率，这构成了核心的临床和商业壁垒26。分析师预计，该长效生长激素管线（结合已获批的Skytrofa）未来可能达到5亿欧元的峰值销售额26。目前华尔街共有15位分析师覆盖该股，一致给予“买入”评级（40%强烈买入，60%买入）26。如果FDA如期批准，Ascendis将完成向多重磅炸弹产品公司的转型。公司还计划于2026年第四季度获得欧洲药品管理局（EMA）的批准9。BioMarin Pharmaceutical (BMRN) - PALYNZIQ (sBLA) 催化剂日期：2026年2月28日 (PDUFA)10适应症：青少年苯丙酮尿症 (Phenylketonuria, PKU) BioMarin的补充生物制品许可申请（sBLA）旨在将PALYNZIQ的适用人群扩展至青少年PKU患者。该申请基于PEGASUS三期临床试验的积极数据。试验结果表明，该药物达到了主要疗效终点，能够显著降低青少年患者体内的苯丙氨酸（Phe）水平，展示了良好的长期代谢控制潜力10。尽管BioMarin在2025年第三季度的总收入为7.76亿美元，因市场渗透和汇率因素略低于华尔街极高的共识预期27，但公司整体基本面依然强劲。其主打产品Voxzogo实现了24%的强劲同比增长，且目前已在全球55个国家和地区上市销售27。此外，公司将2025财年的全年收入指引上调至31.5亿至32亿美元之间27。更重要的是，H.C. Wainwright等投行认为，BioMarin近期对Amicus的战略收购巩固了其长期现金流的持久性，尽管峰值销售的兑现需要等到2030年代28。目前，分析师对BMRN的共识评级为“买入”，平均目标价介于88.94美元至93.66美元之间27。PALYNZIQ的标签扩展属于渐进式利好，投资者更应关注其新任高管团队（如新任首席会计官Rashmi Ramchandani）在成本控制和Voxzogo市场防御上的执行力28。Lantheus Holdings (LNTH) - Piflufolastat F 18 催化剂日期：2026年3月6日 (PDUFA)30适应症：前列腺特异性膜抗原 (PSMA) PET成像新配方 Lantheus通过其附属公司Aphelion提交了市场领先的PSMA PET成像剂PYLARIFY（piflufolastat F 18）的新配方NDA。FDA已将PDUFA目标行动日期设定为2026年3月6日30。在表面上看，这似乎仅是一个简单的配方升级，但从放射性药物产业的底层逻辑来看，这具有深远的商业影响。PYLARIFY在复发性前列腺癌患者中展示了高达86%的中位真阳性率，而常规成像（CT或MRI）的真阳性率仅为28.3%30。这种压倒性的特异性使其成为首个突破10亿美元销售额大关的放射性诊断药物（2025年前九个月净销售额达7.493亿美元）33。然而，放射性药物的最大瓶颈在于F-18同位素的极短半衰期带来的即时供应链压力。此次新配方通过优化制造工艺，预计将批次规模（Batch Size）大幅扩大约50%，并提高了放射性浓度30。这不仅能够显著降低单位销售成本（COGS），推高毛利率，还能使得药物被运输到以往受限于物理衰变而无法触达的偏远医疗中心，极大地扩大了患者的可及性范围30。机构名称分析师日期评级目标价Truist SecuritiesRichard Newitter2025-12-18买入 $82.00 35MizuhoAnthony Petrone2025-12-17跑赢大盘 $72.00 35Goldman SachsPaul Choi2025-10-08中性 (下调) $77.00 35B. Riley FinancialJustin Walsh2025-09-16买入 $84.00 35 如上表所示，华尔街分析师对Lantheus的平均目标价为84.58至85.13美元，隐含着约15%至16%的上涨空间36。在超25亿美元的PSMA PET成像市场中，Lantheus占据了约62.5%的绝对份额33。新配方的获批以及预期获得的三年过渡期通过支付状态（Pass-through payment status），将构建难以逾越的护城河34。长线投资者应将其视为高质量的垄断型资产。Aldeyra Therapeutics (ALDX) - Reproxalap 催化剂日期：2026年3月16日 (PDUFA)7适应症：干眼症 (Dry Eye Disease, DED) Reproxalap是一种首创的小分子反应性醛类物质（RASP）调节剂。该候选药物的监管审批之路充满了戏剧性和极高的二元不确定性。FDA此前已先后两次向Aldeyra发出完全回复信（CRL）。2023年底的首封CRL指出药物未能在控制良好的试验中证明缓解干眼症状的疗效；2025年4月的第二封CRL则对既往干眼室（Dry Eye Chamber）试验的基线差异提出了方法学质疑，并要求进行额外的临床试验40。 Aldeyra随后进行了一项新的三期随机双盲干眼室试验。数据显示，给药后80至100分钟，Reproxalap组的眼部不适症状评分显著低于溶媒组（p=0.002），成功达到主要终点40。基于此，Aldeyra第三次提交了NDA，最初被FDA定于2025年12月16日做出决定40。然而，转折发生在2025年12月12日。FDA要求Aldeyra提交一项“现场试验（Field Trial）”的完整临床研究报告（CSR）作为NDA的重大修正（Major Amendment）。该现场试验评估了患者在真实自然环境中的症状，但未能达到改善干眼症状的主要终点（尽管公司声称数据具有支持性）40。这一修正迫使FDA将PDUFA日期推迟了三个月至2026年3月16日39。关键事件日期状态/影响第三次提交NDA2025年6月17日获得FDA受理解读为“完整第二类回应” 39提交安全性数据2025年8月21日补充长期用药安全性档案 42FDA要求现场试验CSR2025年12月12日触发重大修正，延长审查期 40FDA计划反馈标签要求2026年2月16日关键风向标，未发现重大缺陷则讨论标签 40最新PDUFA目标日期2026年3月16日最终审批决定日 39 深度战略推演：这构成了典型的极高风险二元事件。FDA在急性干眼室数据有效但长期现场环境数据失败之间面临权衡。如果FDA更看重控制环境变量下的生物学机制证明，则有可能获批；如果强调真实世界疗效，则面临第三次CRL的毁灭性打击。目前分析师的共识目标价高达9.50美元（潜在涨幅逾90%）45。保守型投资者应当规避，而激进的对冲基金或可通过跨式期权（Straddle）捕捉即将到来的巨大隐含波动率爆发。Rocket Pharmaceuticals (RCKT) - KRESLADI 催化剂日期：2026年3月28日 (PDUFA)7适应症：严重白细胞黏附缺陷I型 (LAD-I) KRESLADI (marnetegragene autotemcel) 是一种使用慢病毒载体改造患者自身造血干细胞的基因疗法，旨在导入功能性ITGB2基因，恢复CD18蛋白的表达，从而使白细胞能够正常抵抗感染48。LAD-I是一种罕见的遗传性免疫缺陷疾病，患儿面临反复的致命感染，若无骨髓移植，在儿童早期死亡率极高47。从临床数据来看，KRESLADI在1/2期全球临床研究中展现了变革性的疗效：所有接受治疗的患者在输注后12个月及整个随访期间的总体生存率达到了100%47。药物显著减少了严重感染的发生频率，改善了皮肤病变并恢复了伤口愈合能力，且未出现与治疗相关的严重不良事件47。尽管临床数据堪称完美，但该药物的审批却受阻于制造工艺。此前，FDA针对其生物制品许可申请（BLA）发出了完全回复信（CRL），要求提供有限的额外化学、制造和控制（CMC）信息48。在公司重新提交BLA后，FDA接受了该申请并再次授予优先审评，设定了2026年3月28日的PDUFA日期47。如果KRESLADI顺利获批，Rocket不仅将推出其首款商业化产品，更将获得一张极其宝贵的“罕见儿科疾病优先审评凭证（PRV）”47。目前该凭证在二级市场的交易价值约为1.5亿美元。这笔巨额的非稀释性资本注入将彻底重塑公司的资产负债表，大幅延长现金跑道，并为重启因严重不良事件而暂停的另一核心管线——针对Danon病的RP-A501二期试验提供充足弹药48。目前华尔街分析师一致看好其前景，认为FDA的CMC担忧已得到充分解决，建议在PDUFA前逢低吸纳。2026年第二季度重磅PDUFA与监管博弈进入第二季度，FDA的审批焦点将转向市场规模更大、竞争更为激烈的神经科学和免疫学领域。这些资产不仅牵动着巨大商业利益，也验证着新技术平台的成色。Replimune (REPL) - RP1 催化剂日期：2026年4月10日 (PDUFA)7适应症：抗PD-1治疗失败的晚期黑色素瘤 Replimune正在推进其专有的溶瘤免疫疗法（RPx）平台。其核心候选药物RP1（vusolimogene oderparepvec）是一种基因工程化的单纯疱疹病毒（HSV-1），表达促进融合的蛋白（GALV-GP R-）和GM-CSF，旨在最大化肿瘤细胞的杀伤效力并激活系统性抗肿瘤免疫反应14。该药物的监管历程同样经历波折。2025年7月，FDA对RP1联合纳武利尤单抗（nivolumab）的BLA发出了CRL，导致公司股价单日暴跌逾77%54。然而，随后FDA在10月接受了基于第二类重新提交（Class II resubmission）的BLA，并设定了2026年4月10日的PDUFA日期14。支撑此次提交的核心数据包括近期在ESMO大会上公布的肢端黑色素瘤（Acral Melanoma）亚组数据：在抗PD-1失败的患者中，RP1联合疗法实现了44%（8/18）的客观缓解率（ORR），中位缓解持续时间（DOR）长达11.9个月14。为了支持全面批准，公司目前正在推进招募约400名患者的IGNYTE-3确证性三期试验，以总生存期（OS）为主要终点14。财务安全边际方面，Replimune在2026财年第三季度的净亏损为7090万美元，但截至2025年12月31日，公司持有2.691亿美元的现金储备56。此外，公司近期与Hercules Capital重组了债务融资额度，获得了基于里程碑的资金支持，将现金跑道有效延长至2027年第一季度末，足以覆盖初期的商业化启动阶段56。关键财务指标2026财年第三季度同比变化净亏损$70.9M +7% 56研发支出 (R&D)$53.1M +11% 56销售、一般与行政支出 (SG&A)$18.7M +4% 56现金储备 (截至2025年底)$269.1M 足够维持至2027年 57 从机构持仓动向看，临近PDUFA日期，Forbion Capital等专业基金披露了超过280万股的新增持仓，而Readystate Asset Management更是在第三季度大幅增持了约1296%57。华尔街分析师平均目标价约为12.57美元，显示出超过80%的潜在上涨空间56。考虑到公司已完成商业化供应的生产布局14，这排除了上市初期的执行风险。建议长线投资者密切关注其获批情况，溶瘤病毒若能在黑色素瘤中成功破局，将开启整个技术路线的价值重估。Axsome Therapeutics (AXSM) - AXS-05 (sNDA) 催化剂日期：2026年4月30日 (PDUFA)11适应症：阿尔茨海默病激越 (Alzheimer's Disease Agitation, ADA) AXS-05（右美沙芬和安非他酮的复方制剂）利用代谢抑制技术提高右美沙芬的中枢神经系统生物利用度。该药物此前已以商品名Auvelity获批用于治疗成人重度抑郁症（MDD），并在市场上大获成功。2025年前九个月，Auvelity的销售额同比激增77.1%，达到3.52亿美元，年化收入运行率超过5亿美元60。此次提交的补充新药申请（sNDA）旨在将适应症扩展至阿尔茨海默病激越。FDA已授予该申请优先审评资格，PDUFA日期为2026年4月30日58。高达76%的阿尔茨海默病患者会出现激越症状，不仅严重降低患者生活质量，也是导致患者被送入护理机构的主要原因，构成了一个巨大的未满足临床需求58。在名为ACCORD和ADVANCE-2的三期临床试验中，AXS-05展示了强大的疗效。特别是ACCORD试验，在长达26周的双盲维持期中，AXS-05组将激越症状复发的风险相比安慰剂组显著降低了3.6倍（风险比 0.276，p=0.014），且具有良好的安全耐受性，未增加跌倒、镇静或认知能力下降的风险62。投行机构分析师日期评级最新目标价H.C. WainwrightRaghuram Selvaraju2026-01-20买入 $260.00 63JefferiesAndrew Tsai2026-02-03买入 $245.00 63Piper SandlerDavid Amsellem2026-01-16增持 $223.00 63RBC CapitalLeonid Timashev2026-01-21跑赢大盘 $219.00 64Leerink PartnersMarc Goodman2026-01-28跑赢大盘 $205.00 63 华尔街对AXSM的未来极为乐观。Truist Securities预测，由于竞争格局相对空白，即便仅取得约6%的市场渗透率，AXS-05在ADA适应症上的美国峰值销售额就将高达30亿美元61。结合其高达91.86%的毛利率和持续攀升的营收61，Axsome被视为CNS领域商业化最成功的公司之一。分析师一致给出强烈的“买入”评级，平均目标价约为216美元至220美元63。这被视为当前生物医药板块中风险收益比最佳的核心底仓资产之一。Argenx (ARGX) - VYVGART (sBLA) 催化剂日期：2026年5月10日 (PDUFA)11适应症：乙酰胆碱受体抗体（AChR-Ab）血清阴性的全身型重症肌无力（gMG） Argenx 正在稳步推进其宏伟的“Vision 2030”战略，即通过单一分子VYVGART（efgartigimod）及其皮下版本覆盖数十种由IgG介导的自身免疫性疾病67。2025年，Argenx创造了令人瞩目的41.5亿美元全球产品净销售额，同比激增90%，目前全球已有约19,000名患者接受该药物治疗67。此次提交的sBLA旨在将适应症扩展至AChR抗体血清阴性的gMG成人患者。该人群约占所有gMG患者的20%（包括MuSK+、LRP4+及三阴性患者），长期面临无靶向药可用的困境15。在Phase 3 ADAPT SERON研究中，VYVGART展示了卓越的疗效，达到了主要终点（p=0.0068），患者的MG-ADL总分在第4周平均改善了3.35分15。FDA已授予该申请优先审评资格，PDUFA目标日期为5月10日15。如果获批，VYVGART将成为首款也是唯一一款覆盖全部gMG抗体谱系的靶向疗法68。这将在处方医生端形成绝对的垄断壁垒，极大提升市场推广的效率。目前华尔街对ARGX的共识目标价接近1000美元（约987-996美元）69。作为市值突破500亿美元的大型生物科技公司，Argenx不仅在重症肌无力、CIDP等市场确立了领导地位，还将通过其下一代管线empasiprubart继续拓宽护城河67。强烈建议长线投资者在任何宏观回调中加仓该标的。改变疾病治疗范式的关键临床数据读出 (2026年Q1-Q2) 除监管审批外，2026年上半年的几项关键三期临床试验数据读出将直接影响相关疾病领域的千亿美元市场格局，尤以肥胖症、阿尔茨海默病和甲状腺眼病最为瞩目。1. 肥胖症口服世纪大战：Eli Lilly (Orforglipron) vs. Novo Nordisk (Oral Wegovy) 在减肥药的双寡头垄断中，战场正从皮下注射（注射笔）迅速转向每日一次的口服药剂。诺和诺德（Novo Nordisk）的口服版Wegovy（基于大剂量口服索马鲁肽）在2025年底获得了FDA的批准，并在2026年初启动商业化推广71。根据OASIS-4试验数据，口服Wegovy在64周时实现了高达16.6%的平均体重减轻71。然而，由于其作为多肽类药物的特性，患者必须在清晨空腹服用，且服药后半小时内严格禁止进食、饮水或服用其他药物，这在依从性上存在一定瑕疵74。相比之下，礼来（Eli Lilly）的Orforglipron是一种非肽类、小分子GLP-1受体激动剂。在三期ATTAIN-1试验中，最高剂量组在72周时实现了约12.4%的体重减轻71。尽管FDA授予了Orforglipron“国家优先凭证（National Priority Voucher）”以期望加速审评，但最新的内部文件显示，FDA已将PDUFA目标行动日期延长至2026年4月10日12。维度Novo Nordisk (口服 Wegovy)Eli Lilly (Orforglipron)分子类型多肽类 GLP-1 类似物非肽类小分子 GLP-1 激动剂 71临床减重效果 16.6% (64周，OASIS-4) 71 12.4% (72周，ATTAIN-1) 71依从性与限制空腹服用，服后需禁食禁水半小时无食物禁忌，随时服用 74监管状态已获批并上市 (2026年初) 73 PDUFA 预计为 2026年4月10日 12生产可扩展性受限于多肽产能与供应链极强的小分子合成与量产优势 71 深度产业分析揭示了礼来的底牌：供应链可扩展性（Scalability）。最新的SEC文件披露，截至2025年12月31日，礼来已经囤积了价值惊人的1.5亿美元的“上市前库存（Pre-launch Inventories）”，其中绝大部分正是Orforglipron77。这一罕见的巨额库存拨备表明，礼来准备在药物获批次日发动全球闪电战。由于小分子的合成成本远低于多肽，Orforglipron不仅能够完全解决产能短缺问题，挤出市场上的复方仿制药（Compounders），还具备在价格战中彻底摧毁竞争对手利润率的潜力71。这场战役的胜负不取决于单纯的减重数字，而在于谁能用最低的成本将药物送到数亿超重患者的床头柜上。2. 阿尔茨海默病的给药革命：Eli Lilly (Remternetug) 阿尔茨海默病领域的焦点将集中在礼来即将公布的Remternetug三期TRAILRUNNER-ALZ 1试验数据上，该试验预计于2026年3月完成79。 Remternetug被寄予厚望，旨在成为礼来已获批药物Kisunla (donanemab) 的下一代接班人79。当前靶向淀粉样蛋白的单抗药物（包括Biogen的Leqembi）最大的临床痛点在于必须频繁前往输液中心进行长时间的静脉注射（IV），这极大地消耗了本就短缺的医疗资源，并加重了老年患者和家属的负担。 TRAILRUNNER-ALZ 1试验招募了1600多名早期症状性阿尔茨海默病患者，关键在于它同时评估了Remternetug的静脉注射和皮下注射（Subcutaneous, SubQ）配方79。如果皮下注射（采用类似EpiPen的自动注射笔）能够证明在清除大脑淀粉样蛋白斑块上具有不劣于IV配方的疗效80，这将从根本上改变阿尔茨海默病的治疗范式，实现居家用药。一季度末或年中的学术会议数据发布，将是决定礼来能否彻底主导该千亿级市场的关键节点。3. 甲状腺眼病 (TED) 市场的格局重塑：Viridian Therapeutics (VRDN) Viridian Therapeutics正在通过静脉和皮下双重管线，对Amgen的Tepezza（此前垄断TED市场）发起猛烈冲击。一方面，其静脉注射药物Veligrotug已展现出卓越的疗效：在针对慢性TED的THRIVE-2三期试验中，仅仅5次输注（Tepezza需8次）后，高达56%的患者实现了复视（Diplopia）响应，32%的患者获得了复视的完全缓解，同时眼球突出（Proptosis）显著减少了2.34mm84。由于其副作用（如听力损伤）的发生率明显低于竞争对手（安慰剂调整后的听力损伤率为5%，且无完全失聪病例）85，FDA已授予其优先审评资格，PDUFA目标日期定为2026年6月30日16。另一方面，更为重磅的催化剂是其皮下注射药物Elegrobart（VRDN-003）。针对活动性TED的REVEAL-1三期研究的顶线数据预计将于2026年第一季度（约3月份）发布17。Elegrobart被设计为通过低容量自动注射器实现患者每4周或8周一次的居家自我注射17。如果数据积极，它将彻底终结TED患者必须在医疗机构进行数小时静脉输注的痛苦历史。凭借“一流的疗效+极致的便利性”，Viridian有望迅速占据这个年化超20亿美元的庞大市场17。鉴于其极高的并购吸引力，建议投资者在REVEAL-1数据发布前构建多头头寸。FDA咨询委员会 (AdCom) 动向与系统性影响在跟踪单个企业催化剂的同时，FDA的疫苗和相关生物制品咨询委员会（VRBPAC）会议同样具备重大的行业指导意义。 2026年3月12日，VRBPAC将召开公开会议，讨论并就2026-2027年美国流感季节的流感病毒疫苗毒株组成提出建议87。虽然这是一年一度的常规议程，但在2026年的背景下却暗流涌动。近期，Moderna（MRNA）就其首创的季节性mRNA流感疫苗（mRNA-1010）与FDA爆发了罕见的公开争执2。核心分歧在于FDA要求采用更为苛刻的传统对比标准来评估mRNA疫苗的疗效。尽管经过周旋，FDA同意受理申请，并将针对65岁及以上人群的加速批准以及50至64岁人群的完全批准设定了2026年8月5日的PDUFA目标日期2，但这反映出FDA内部对新型疫苗技术平台的审慎态度。投资者应高度关注3月12日会议的专家问答环节和最终会议纪要（Minutes）。如果流行病学家在会议中强调流感病毒株突变预测的高度不确定性，且认为传统鸡胚培养法生产疫苗的周期过于漫长，这将从侧面极大地利好mRNA技术路线（其具备在数周内完成毒株序列更新和规模化量产的巨大优势）。该会议定调将直接影响下半年市场对Moderna等企业疫苗管线的估值预期。投资组合构建与结构性策略建议综合上述对2026年第一和第二季度宏观监管环境、核心PDUFA事件及重磅临床数据读出的多维分析，我们为机构及专业投资者提出以下“哑铃型（Barbell）”生物医药资产配置策略：一、基石增长组合（低监管风险，强基本面与自由现金流支撑）本组资产旨在提供对抗宏观利率波动的稳健收益，重点布局已消除二元风险、即将进入爆炸式销售放量或垄断格局进一步强化的龙头企业。 1.Axsome Therapeutics (AXSM)：凭借Auvelity在抑郁症市场的巨大成功，AXS-05在4月份几乎确定获批阿尔茨海默病激越（ADA）适应症。面对30亿美元的真空市场和近92%的毛利率，AXSM是当前最具配置价值的中型核心成长股。 2.Argenx (ARGX)：作为市值超500亿美元的巨头，5月份VYVGART血清阴性适应症的获批将使其成为重症肌无力领域的终极统治者。其卓越的商业化执行力使其成为抵御周期波动的完美选择。 3.Lantheus Holdings (LNTH)：3月份新配方的获批不仅将毛利率提升至新高，扩大产能更将彻底锁死前列腺癌PET成像诊断的百亿美元蓝海。二、高弹性阿尔法组合（高赔率，受关键催化剂驱动）本组资产聚焦于即将迎来决定命运的PDUFA或三期数据读出的标的，适合通过严格控制仓位或利用期权组合策略（如跨式/宽跨式期权）来捕获非对称收益。 1.Rocket Pharmaceuticals (RCKT)：3月末的PDUFA。其基因疗法对LAD-I的100%生存率提供了极高临床确定性，只要FDA认可其改善后的CMC工艺，获批带来的1.5亿美元优先审评凭证（PRV）价值将瞬间重塑公司的估值体系。 2.Viridian Therapeutics (VRDN)：一季度的皮下注射（SubQ）三期数据是决定性战役。若其低频居家给药被证明有效，不仅将瓦解竞争对手的防线，极有可能在年内触发大型制药公司的溢价并购。 3.Replimune (REPL)：4月份的PDUFA。溶瘤病毒在抗PD-1失败黑色素瘤中的巨大潜力与FDA要求的长期确证性试验之间存在博弈，适合在数据真空期结合对冲工具进行多空操作。三、结构性规避与风险预警 1.Aldeyra Therapeutics (ALDX)：3月中旬的PDUFA伴随着极高的监管红旗（Red Flags）。真实世界现场试验的失败以及FDA反复要求的临床报告（CSR），构成了第三次被拒（CRL）的巨大隐患。建议保守型资金坚决回避此类胜率模糊的“赌博式”事件。 2.减重赛道的产能之战（LLY vs. NVO）：虽然礼来和诺和诺德的口服药大战引人瞩目，但投资重点应从“临床数据谁更好”转移至“谁的工厂造得更快”。礼来15亿美元的上市前小分子库存是一个危险的护城河信号，投资者在加注多肽类减重药供应链企业时需警惕技术路线迭代带来的需求坍塌风险。引用的著作 1.Short Takes and Updates—February 20, 2026 | FDA Matters, 访问时间为二月 23, 2026，https://www.fdamatters.com/short-takes-and-updates-february-20-2026/ 2.Moderna says the FDA will consider its new flu shot after resolving a public dispute, 访问时间为二月 23, 2026，https://apnews.com/article/moderna-flu-vaccine-mrna-fda-kennedy-844ddc1d763a3975a0a2af6f67d5895e 3.Give AI investment the big come hither, 访问时间为二月 23, 2026，https://m.economictimes.com/opinion/et-editorial/give-ai-investment-the-big-come-hither/articleshow/128391704.cms 4.AI-biotech sovereignty will define India’s future, 访问时间为二月 23, 2026，https://m.economictimes.com/opinion/et-commentary/kiran-mazumdar-shaw-ai-biotech-sovereignty-will-define-indias-future/articleshow/128570938.cms 5.Why small, application-specific models are India's path forward in AI, 访问时间为二月 23, 2026，https://m.economictimes.com/opinion/et-commentary/why-small-application-specific-models-are-indias-path-forward-in-ai/articleshow/128477042.cms 6.Speed of scientific discovery has itself become a strategic asset, with AI as the super-accelerator, 访问时间为二月 23, 2026，https://m.economictimes.com/opinion/et-commentary/speed-of-scientific-discovery-has-itself-become-a-strategic-asset-with-ai-as-the-super-accelerator/articleshow/128391154.cms 7.Biotech Catalyst Calendar 2026 | PDUFA Dates, FDA Decisions, 访问时间为二月 23, 2026，https://clinicalalpha.ai/catalyst-calendar 8.Vanda Pharmaceuticals Announces FDA Approval of BYSANTI, 访问时间为二月 23, 2026，https://vandapharmaceuticalsinc.gcs-web.com/node/16771/pdf 9.Biotech FDA Catalyst Database | FDA Catalyst Calendar | Clinical, 访问时间为二月 23, 2026，https://app.bpiq.com/ 10.PDUFA Dates, FDA Approval Dates | BiopharmIQ, 访问时间为二月 23, 2026，https://app.bpiq.com/pdufa-calendar 11.Upcoming FDA Events & PDUFA Dates - MarketBeat, 访问时间为二月 23, 2026，https://www.marketbeat.com/fda-calendar/upcoming/ 12.FDA Delays Decision for Lilly's Obesity Pill Orforglipron ... - BioSpace, 访问时间为二月 23, 2026，https://www.biospace.com/fda/fda-delays-decision-for-lillys-obesity-pill-orforglipron-other-priority-voucher-awardees-report 13.Aldeyra Therapeutics (ALDX) Stock Forecast and Price Target 2026, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/ALDX/forecast/ 14.Replimune Reports Fiscal Third Quarter 2026 Financial Results and, 访问时间为二月 23, 2026，https://ir.replimune.com/news-releases/news-release-details/replimune-reports-fiscal-third-quarter-2026-financial-results/ 15.argenx Announces FDA Acceptance of Supplemental ... - argenx, 访问时间为二月 23, 2026，https://argenx.com/news/2026/press-release-3217457 16.Viridian Therapeutics Announces BLA Acceptance and Priority, 访问时间为二月 23, 2026，https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx 17.Viridian Therapeutics Prepares for Transformational 2026, 访问时间为二月 23, 2026，https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Prepares-for-Transformational-2026/default.aspx 18.FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and, 访问时间为二月 23, 2026，https://www.psychiatrictimes.com/view/fda-approves-bysanti-for-treatment-of-bipolar-1-disorder-and-schizophrenia 19.Investors - Vanda Pharmaceuticals, 访问时间为二月 23, 2026，https://www.vandapharma.com/investors 20.FDA Approves Milsaperidone for Treatment of Bipolar I Disorder and, 访问时间为二月 23, 2026，https://www.geneonline.com/fda-approves-milsaperidone-for-treatment-of-bipolar-i-disorder-and-schizophrenia/ 21.FDA Calendar - Upcoming Drug Approval & PDUFA Dates, 访问时间为二月 23, 2026，https://www.biopharmawatch.com/fda-calendar 22.Vanda Pharma Stock Surges 44% After FDA Approves Bysanti, 访问时间为二月 23, 2026，https://www.multibagg.ai/market-pulse/articles/vanda-pharma-stock-fda-approval-cmlvv7xz7gkmxo50j4iotzse7 23.Biotech Catalyst Calendar February 2026: PDUFA, BLA & Clinical, 访问时间为二月 23, 2026，https://www.merlintrader.com/biotech-catalyst-calendar-february-2026/ 24.Eton Pharmaceuticals (ETON) Stock Forecast and Price Target 2026, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/ETON/forecast/ 25.BiopharmaWatch: FDA Calendar, PDUFA Dates & Biotech Catalysts, 访问时间为二月 23, 2026，https://www.biopharmawatch.com/ 26.Ascendis Pharma (ASND) Stock Forecast: Analyst Ratings ..., 访问时间为二月 23, 2026，https://public.com/stocks/asnd/forecast-price-target 27.BioMarin Pharmaceutical (BMRN) Stock Forecast: Analyst Ratings ..., 访问时间为二月 23, 2026，https://public.com/stocks/bmrn/forecast-price-target 28.BioMarin stock price target raised to $60 from $55 at HC Wainwright, 访问时间为二月 23, 2026，https://www.investing.com/news/analyst-ratings/biomarin-stock-price-target-raised-to-60-from-55-at-hc-wainwright-93CH-4419237 29.BioMarin Pharmaceutical Inc Analyst Ratings - BMRN - Benzinga, 访问时间为二月 23, 2026，https://www.benzinga.com/quote/BMRN/analyst-ratings 30.Lantheus Announces FDA Acceptance of NDA for New Formulation, 访问时间为二月 23, 2026，https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-fda-acceptance-nda-new-formulation-market 31.FDA accepts NDA for new formulation of piflufolastat F 18 in prostate, 访问时间为二月 23, 2026，https://www.urologytimes.com/view/fda-accepts-nda-for-new-formulation-of-piflufolastat-f-18-in-prostate-cancer 32.Lantheus (LNTH) FDA Approvals, PDUFA Dates & Drug Alerts 2026, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/LNTH/fda-events/ 33.Lantheus Holdings, Inc. (LNTH) SWOT Analysis - DCFmodeling.com, 访问时间为二月 23, 2026，https://dcfmodeling.com/products/lnth-swot-analysis 34.Lantheus Reports Third Quarter 2025 Financial Results and, 访问时间为二月 23, 2026，https://investor.lantheus.com/node/16636/pdf 35.Lantheus (LNTH) Stock Forecast and Price Target 2026 - MarketBeat, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/LNTH/forecast/ 36.What is the current Price Target and Forecast for Lantheus (LNTH), 访问时间为二月 23, 2026，https://www.zacks.com/stock/research/LNTH/price-target-stock-forecast 37.LNTH / Lantheus Holdings, Inc. (NasdaqGM) - Forecast, Price Target, 访问时间为二月 23, 2026，https://fintel.io/sfo/us/lnth 38.LANTHEUS HOLDINGS INC (LNTH) Stock Analyst Ratings - ChartMill, 访问时间为二月 23, 2026，https://www.chartmill.com/stock/quote/LNTH/analyst-ratings 39.Aldeyra Therapeutics Announces PDUFA Extension of the New, 访问时间为二月 23, 2026，https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-pdufa-extension-new-drug 40.FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to, 访问时间为二月 23, 2026，https://www.hcplive.com/view/fda-extends-pdufa-date-for-reproxalap-in-dry-eye-disease-to-march-2026 41.Aldeyra Therapeutics (ALDX) FDA Approvals - MarketBeat, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/ALDX/fda-events/ 42.FDA extends Aldeyra's reproxalap PDUFA after requesting, 访问时间为二月 23, 2026，https://www.ophthalmologytimes.com/view/fda-extends-aldeyra-s-reproxalap-pdufa-after-requesting-additional-clinical-study-report 43.FDA extends reproxalap's PDUFA to March 2026, 访问时间为二月 23, 2026，https://glance.eyesoneyecare.com/stories/2025-12-16/fda-extends-reproxalap-s-pdufa-to-march-2026/ 44.Aldeyra Extends NDA Review for Dry Eye Treatment to March 2026, 访问时间为二月 23, 2026，https://intellectia.ai/news/etf/aldeyra-extends-nda-review-for-dry-eye-treatment-to-march-2026 45.ALDX Stock Forecast 2026 - Aldeyra Price Targets & Predictions, 访问时间为二月 23, 2026，https://tickernerd.com/stock/aldx-forecast/ 46.aldx - Aldeyra Therapeutics, Inc. Stock Price - Perplexity, 访问时间为二月 23, 2026，https://www.perplexity.ai/finance/ALDX/research 47.News Release Details - Rocket Pharmaceuticals, Inc., 访问时间为二月 23, 2026，https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-acceptance-bla-resubmission/ 48.Rocket Pharmaceuticals (RCKT) FDA Approvals - MarketBeat, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/RCKT/fda-events/ 49.RCKT Rocket Pharmaceuticals | Merlintrader Trading Pub, 访问时间为二月 23, 2026，https://www.merlintrader.com/rckt-rocket-pharmaceuticals-2/ 50.FDA Decisions to Look For in 1H 2026 - CGTLive®, 访问时间为二月 23, 2026，https://www.cgtlive.com/view/fda-decisions-look-1h-2026 51.Rocket Pharmaceuticals Reports Third Quarter 2025 Financial, 访问时间为二月 23, 2026，https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-reports-third-quarter-2025-financial/ 52.Rocket Pharma (RCKT) Stock Forecast: Analyst Ratings, Predictions, 访问时间为二月 23, 2026，https://public.com/stocks/rckt/forecast-price-target 53.Replimune stock rating upgraded by BMO Capital on improved FDA, 访问时间为二月 23, 2026，https://uk.investing.com/news/analyst-ratings/replimune-stock-rating-upgraded-by-bmo-capital-on-improved-fda-outlook-93CH-4340821 54.Exploring Replimune Group, Inc. (REPL): Who s Buying and Why?, 访问时间为二月 23, 2026，https://dcfmodeling.com/blogs/investors/repl-investor-profile 55.Replimune Announces FDA Acceptance of BLA Resubmission of, 访问时间为二月 23, 2026，https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-acceptance-bla-resubmission-rp1-0/ 56.Replimune Beats EPS as RP1 FDA Decision Nears April 10 | Fintool, 访问时间为二月 23, 2026，https://fintool.com/app/research/companies/REPL/earnings/Q3%202026 57.Replimune Group, Inc. Stock Price - Perplexity, 访问时间为二月 23, 2026，https://www.perplexity.ai/finance/REPL 58.Axsome Therapeutics Announces FDA Acceptance and Priority, 访问时间为二月 23, 2026，https://axsometherapeuticsinc.gcs-web.com/node/12596/pdf 59.AXS-05 Gets FDA Priority Review for Alzheimer's Agitation Treatment, 访问时间为二月 23, 2026，https://www.towardshealthcare.com/news/alzheimers-agitation-fda-priority-review 60.AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's, 访问时间为二月 23, 2026，https://www.zacks.com/stock/news/2811323/axsm-up-on-fda-priority-review-to-axs-05-snda-in-alzheimers-agitation 61.Truist Securities reiterates Buy rating on Axsome Therapeutics stock ..., 访问时间为二月 23, 2026，https://www.investing.com/news/analyst-ratings/truist-securities-reiterates-buy-rating-on-axsome-therapeutics-stock-93CH-4427856 62.FDA Accepts, Grants Priority Review to AXS-05 sNDA for ... - HCPLive, 访问时间为二月 23, 2026，https://www.hcplive.com/view/fda-accepts-grants-priority-review-to-axs-05-snda-for-alzheimer-s-disease-agitation 63.Axsome Therapeutics (AXSM) Stock Forecast and Price Target 2026, 访问时间为二月 23, 2026，https://www.marketbeat.com/stocks/NASDAQ/AXSM/forecast/ 64.AXSM Stock Forecast 2026 - Axsome Price Targets & Predictions, 访问时间为二月 23, 2026，https://tickernerd.com/stock/axsm-forecast/ 65.AXSM - Axsome Therapeutics, Inc. - Data Insights Market, 访问时间为二月 23, 2026，https://www.datainsightsmarket.com/companies/AXSM 66.AXSM Stock Price | Analyst Target 220.22 & Consensus - eToro, 访问时间为二月 23, 2026，https://www.etoro.com/markets/axsm 67.argenx Highlights 2026 Strategic Priorities, 访问时间为二月 23, 2026，https://argenx.com/news/2026/press-release-3216531 68.Argenx's VYVGART Moves Closer To Expanded MG Use As FDA, 访问时间为二月 23, 2026，https://www.nasdaq.com/articles/argenxs-vyvgart-moves-closer-expanded-mg-use-fda-grants-priority-review 69.argenx (ARGX) Stock Forecast: Analyst Ratings, Predictions & Price, 访问时间为二月 23, 2026，https://public.com/stocks/argx/forecast-price-target 70.argenx SE Stock Price: Quote, Forecast, Splits & News (ARGX), 访问时间为二月 23, 2026，https://www.perplexity.ai/finance/ARGX 71.Novo Nordisk wegovy pill is more effective than Eli Lilly's ... - Reddit, 访问时间为二月 23, 2026，https://www.reddit.com/r/ValueInvesting/comments/1qskwpv/novo_nordisk_wegovy_pill_is_more_effective_than/ 72.FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026, 访问时间为二月 23, 2026，https://www.investing.com/analysis/fda-approves-novo-nordisks-wegovy-pill-a-game-changer-for-2026-200672572 73.Outlook for Obesity in 2026: From Consolidation to Acceleration, 访问时间为二月 23, 2026，https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026 74.Is Oral Wegovy a Game Changer for Novo Nordisk? - Finviz, 访问时间为二月 23, 2026，https://finviz.com/news/281464/is-oral-wegovy-a-game-changer-for-novo-nordisk 75.Five drug approvals to watch in 2026 | Drug Discovery News, 访问时间为二月 23, 2026，https://www.drugdiscoverynews.com/five-drug-approvals-to-watch-in-2026-16982 76.Novo's Wegovy Pill Success Is 'Good News' for Orforglipron, Lilly, 访问时间为二月 23, 2026，https://www.biospace.com/novos-wegovy-pill-success-is-good-news-for-orforglipron-lilly-execs-say 77.Lilly builds sizable store of orforglipron ahead of FDA verdict, 访问时间为二月 23, 2026，https://www.fiercepharma.com/pharma/lillys-pre-launch-inventory-oral-glp-1-candidate-swells-ahead-expected-fda-obesity-nod 78.Lilly, chasing Novo, expects second-quarter FDA decision on, 访问时间为二月 23, 2026，https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/ 79.5 Clinical Readouts to Watch in H1 2026 - BioSpace, 访问时间为二月 23, 2026，https://www.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026 80.NCT05463731 | A Study of Remternetug (LY3372993) in, 访问时间为二月 23, 2026，https://clinicaltrials.gov/study/NCT05463731 81.Remternetug | ALZFORUM, 访问时间为二月 23, 2026，https://www.alzforum.org/therapeutics/remternetug 82.Alzheimer's Disease Market Outlook and Trends - DelveInsight, 访问时间为二月 23, 2026，https://www.delveinsight.com/blog/alzheimers-disease-market 83.Looking Ahead - New Alzheimer's Drugs That Could Be Approved, 访问时间为二月 23, 2026，https://k2med.com/blog/looking-ahead-new-alzheimers-drugs-that-could-be-approved-soon/ 84.Viridian Therapeutics sees stock soar after Phase III TED success, 访问时间为二月 23, 2026，https://www.clinicaltrialsarena.com/news/viridian-therapeutics-sees-stock-soar-after-phase-iii-ted-success/ 85.Viridian Therapeutics stock target upgraded, keeps buy on, 访问时间为二月 23, 2026，https://www.investing.com/news/analyst-ratings/viridian-therapeutics-stock-target-upgraded-keeps-buy-on-veligrotug-outlook-93CH-3722838 86.Filings - Quarterly Results - Viridian Therapeutics, Inc., 访问时间为二月 23, 2026，https://investors.viridiantherapeutics.com/filings/quarterly-results/default.aspx 87.FDA Meetings, Conferences and Workshops, 访问时间为二月 23, 2026，https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops 88.Advisory Committee Calendar - FDA, 访问时间为二月 23, 2026，https://www.fda.gov/advisory-committees/advisory-committee-calendar 89.Vaccines and Related Biological Products Advisory Committee, 访问时间为二月 23, 2026，https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-march-12-2026-meeting-announcement 90.Federal Register/Vol. 91, No. 29/Thursday, February 12, 2026/Notices, 访问时间为二月 23, 2026，https://www.govinfo.gov/content/pkg/FR-2026-02-12/pdf/2026-02787.pdf 91.Federal Register, Volume 91 Issue 29 (Thursday, February 12, 2026), 访问时间为二月 23, 2026，https://downloads.regulations.gov/FDA-2026-N-0826-0001/content.html

疫苗孤儿药临床3期引进/卖出加速审批

2026-02-17

·GlobeNewswire-Health Care

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (CNS) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (CNS) drug delivery designed to deliver drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and Johnson & Johnson (NYSE: JNJ). Central nervous system disorders such as brain cancer, Alzheimer’s Disease, Parkinson’s Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine. The convergence of CNS and oncology makes Oncotelic’s update on expanding international IP coverage for OT-101 even more impactful. Oncotelic Therapeutics’ focus on delivery approaches relevant to CNS and oncology aligns with the industry’s direction. Oncotelic Therapeutics’ development of OT-101 demonstrates its advanced R&D capabilities and innovative repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research. Oncotelic Therapeutics positions itself with a diversified portfolio spanning oncology-focused therapies, CNS indications and delivery technologies. Click here to view the custom infographic of the Oncotelic Therapeutics editorial. Big Pharma’s Shift Toward Proven Assets Biopharma dealmaking has increasingly centered on external innovation, licensing, and acquisitions of assets that demonstrate clinical validation. Strategic analyses from McKinsey & Company describe continued reliance on partnerships and acquisitions to replenish pipelines as internal R&D productivity challenges persist. Similarly, Deloitte’s life sciences M&A outlook highlights ongoing selectivity and capital discipline, encouraging companies to prioritize assets with clearer development paths and measurable progress toward commercialization. This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry. Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success. Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets. Oncotelic Therapeutics fits this strategic profile through its clinical-stage pipeline focused on oncology and CNS-related targets. A clinical-stage biopharmaceutical developer, the company is pursuing therapies for cancer and other serious conditions. Oncotelic’s programs, including those targeting TGF-β signaling and delivery-focused approaches, align with the broader industry emphasis on validated mechanisms and diversified development strategies. CNS, Oncology Markets Are Converging Central nervous system disorders represent one of the largest and most challenging therapeutic categories in modern medicine. The World Health Organization reports that neurological conditions are now among the leading causes of disability and illness worldwide, affecting more than one in three people globally. The growing burden of neurodegenerative disease has intensified the need for innovative treatments capable of addressing complex biological mechanisms. Alzheimer’s disease illustrates the scale of this unmet need. The Alzheimer’s Association estimates that millions of Americans currently live with the disease and that the economic burden continues to rise sharply, reflecting both healthcare costs and societal impact. Parkinson’s disease shows similar trends, with prevalence expected to increase as populations age, reinforcing the long-term importance of CNS therapeutic innovation. The intersection between oncology and CNS research is becoming increasingly relevant because many biological pathways operate across disease categories. Immune regulation, inflammation and signaling pathways involved in tumor progression can also influence neurological disease processes. These overlaps create opportunities for therapeutic platforms that can be developed across multiple indications, potentially expanding commercial reach while leveraging shared scientific insights. From an investment perspective, cross-indication platforms may offer strategic advantages by enabling companies to pursue multiple markets simultaneously. Pharmaceutical companies evaluating acquisitions often look for mechanisms that extend beyond a single indication, as this can increase potential return on investment and support lifecycle management strategies. Oncotelic Therapeutics’ development strategy reflects this convergence by focusing on pathways such as TGF-β modulation, which has been extensively studied in oncology and immune regulation contexts. Research documents the role of TGF-β signaling in cancer biology and tumor microenvironment regulation. By targeting mechanisms relevant across multiple disease categories, the company aligns with the broader trend toward integrated therapeutic platforms. New Milestones Expand Long-Term Potential This convergence makes Oncotelic’s update on expanding international IP coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, even more impactful. The company, along with Sapu Bioscience, noted that the platform “[strengthens] protection across neurology, oncology, and central nervous system (CNS) drug delivery.” OT-101 has multiple prior clinical trials conducted in various oncology indications including glioblastoma and pancreatic cancers. The compound was also investigated for additional applications in Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related inflammatory conditions. Building on its established clinical foundation in oncology, the Company is advancing OT-101 as a broader central nervous system (CNS)-capable therapeutic platform, supported by targeted delivery technologies and expanded intellectual property coverage. The update noted that in Australia, the company has received allowed patent claims explicitly covering OT-101 for the treatment of Parkinson's disease, while in China and Germany, utility model patents have been granted that provide device-level protection for continuous intracranial infusion technologies relevant to CNS therapeutics. “Collectively, these IP developments establish an integrated OT-101 CNS commercialization platform, combining therapeutic use claims in neurology with granted delivery-device protection,” stated the company, which believes this expanded IP estate enhances OT-101's strategic value and supports future development, partnering, and commercialization efforts across oncology and neurological indications. “OT-101 has a well-established clinical foundation, including prior clinical trials in multiple oncology indications, including glioblastoma, and these new IP milestones significantly expand its long-term potential,” said Oncotelic CEO Dr. Vuong Trieu. “By securing Parkinson's disease claims in Australia and strengthening CNS delivery protection in China and Germany, we are building a globally defensible platform that supports both therapeutic use and delivery, while positioning the company for strategic partnerships and long-term shareholder value creation.” Drug Delivery Emerges as Strategic Differentiator Drug delivery has become an increasingly important focus area within biotech innovation, particularly for CNS therapies. The blood–brain barrier presents a significant biological obstacle, preventing many drugs from reaching effective concentrations within brain tissue. Peer-reviewed research highlights that this barrier can limit therapeutic success even when a drug demonstrates strong activity in preclinical models. Because of these challenges, delivery technologies capable of improving targeting or bioavailability are gaining strategic importance. Researchers increasingly view delivery systems as enabling technologies that can unlock previously inaccessible therapeutic pathways. Rather than viewing delivery as secondary to molecular discovery, investors and developers are recognizing it as a critical component of therapeutic success. Regulatory agencies also acknowledge the importance of delivery innovation. The U.S. Food and Drug Administration maintains specific frameworks for evaluating combination products that integrate drug and device components, underscoring the role administration methods play in clinical outcomes From a strategic standpoint, companies developing delivery technologies alongside therapeutic mechanisms may offer differentiated value propositions. Improved delivery can enhance safety, reduce systemic toxicity, or increase efficacy by concentrating treatment within target tissues. Oncotelic Therapeutics’ focus on delivery approaches relevant to CNS and oncology aligns with this industry direction. By emphasizing methods that may enhance therapeutic targeting and overcome biological barriers, the company operates within a segment increasingly viewed as a critical bottleneck, and therefore a strategic value driver, in modern drug development. Platform Repositioning Drives Capital Efficiency Biotech strategy increasingly emphasizes capital efficiency, and one emerging approach involves repositioning clinically validated mechanisms into additional therapeutic indications. Rather than starting from entirely new discovery programs, companies are expanding existing platforms into adjacent markets where scientific rationale already exists. This strategy can reduce risk because safety data and mechanistic understanding from earlier studies may inform future development pathways. Repositioning also allows companies to maximize the value of prior investments by generating multiple clinical opportunities from a single biological target or technology platform. The TGF-β pathway provides a strong example of this approach. Extensive scientific literature describes its role in tumor growth, immune modulation and inflammation, creating opportunities for therapies targeting this pathway across multiple diseases. Advances in understanding tumor microenvironment biology have renewed interest in therapeutic strategies that modulate TGF-β signaling. Oncotelic Therapeutics’ development of OT-101, which targets TGF-β2 mRNA, illustrates a repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research. Studies investigating OT-101 in combination with standard therapies reflect ongoing efforts to expand its potential clinical applications. Platform repositioning may also enhance strategic flexibility for potential partners or acquirers. Companies capable of adapting mechanisms to multiple disease contexts can respond to evolving market conditions or regulatory landscapes, increasing long-term development optionality. Diversified Pipelines Reduce Binary Investment Risk Historically, biotech investment has often centered on single-asset companies, where success or failure depended heavily on one clinical outcome. However, diversified pipelines are increasingly viewed as advantageous because they distribute risk across multiple programs and timelines. A multiasset strategy can provide resilience during clinical development, as setbacks in one program may be offset by progress in others. This diversification can also create multiple value inflection points, attracting investors seeking reduced exposure to binary outcomes while maintaining exposure to breakthrough innovation. From an M&A perspective, diversified pipelines may increase strategic appeal because acquirers gain optionality. A single acquisition can provide access to multiple therapeutic candidates, allowing pharmaceutical companies to prioritize programs based on evolving market needs or scientific progress. As the biotech industry continues to emphasize late-stage validation, platform versatility and capital efficiency, companies combining diversified clinical programs with differentiated scientific approaches may increasingly attract attention from strategic partners and acquirers seeking to balance innovation with reduced development risk. Oncotelic Therapeutics positions itself within this diversified model through a portfolio spanning oncology-focused therapies, CNS indications and delivery technologies. The company’s pipeline includes multiple assets at varying development stages, which may reduce reliance on a single program outcome while supporting broader strategic positioning. Pharma Deals Signal Strategic Shift The pharmaceutical space continues to evolve through strategic partnerships, targeted acquisitions and collaborative innovation designed to accelerate drug development and expand therapeutic pipelines. Recent announcements across the sector highlight a focus on neurological disorders, RNA-based therapies and AI-driven research approaches, reflecting how leading operators are positioning themselves to capture future growth opportunities while addressing significant unmet medical needs. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported a global licensing and collaboration agreement with Novartis. The agreement is for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s disease, and for other additional collaboration targets that will utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiM[TM]) platform. Upon closing, Arrowhead will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales. MeiraGTx Holdings plc (NASDAQ: MGTX) announced the formation of a joint venture with Hologen Limited. According to the announcement, MeiraGTx will receive $200 million in upfront cash at closing of the JV, called Hologen Neuro AI Ltd. In addition to the $200 million upfront payment to MeiraGTx, Hologen Neuro AI will be funded with committed capital of up to $230 million from Hologen to fully finance the development of AAV-GAD for the treatment of Parkinson’s disease through to commercialization, as well as funding earlier stage clinical programs in the CNS, including AAV-BDNF for genetic obesity. Hologen will contribute its proprietary multi-modal generative foundation models (LMMs) to the joint venture. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) completed the acquisition of Sage Therapeutics for approximately $561 million upfront, with contingent value rights (CVR) that could bring total consideration up to about $795 million. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE(R) (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression. Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies in a $14.6 billion transaction. Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of therapeutics for CNS disorders. With this agreement, Johnson & Johnson adds Intra-Cellular Therapies’ CAPLYTA(R)(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate. These developments underscore a broader transformation underway in pharma, where collaboration, platform technologies and portfolio expansion are becoming central to long-term strategy. As companies pursue high-value deals and innovative partnerships, investors and industry observers alike are watching closely to see how these initiatives translate into clinical advancement, commercial success and sustained competitive advantage. For more information, visit Oncotelic Therapeutics profile. About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.comBioMedWire is powered by IBN

并购引进/卖出上市批准

2026-02-17

·智享药界

2025年生物医药行业并购及BD交易盘点分析(Nature & J.P.Morgan)

2025年的生物制药交易合作已引发不少关注，这主要得益于今年宣布的一系列引人注目的并购交易。本文将盘点本年度迄今价值最高的生物制药交易。据DealForma数据显示，2025年上半年共达成逾280宗并购交易，数量为2020年以来之最。今年伊始便出现了金额最高的并购案——强生公司以146亿美元收购Intra-Cellular Therapies公司及其核心资产Caplyta。随后大型并购接踵而至：默克公司以100亿美元收购维罗纳制药，礼来公司收购Scorpion Therapeutics，这些交易有望为后续并购活动释放积极信号。许可协议同样层出不穷，其中预付款项增幅显著。本年度研发许可交易额之最当属葛兰素史克与中国江苏恒瑞医药达成的合作，双方将共同开发包括恒瑞HRS-982在内的一系列药物，该药物适用于慢性阻塞性肺疾病。这笔交易折射出近期备受关注的行业趋势——大型药企正加速从中国引进许可。今年约38%的大型药企交易及28%的预付款项流向中国生物制药公司。 Top 10 biopharma mergers and acquisitions ranked by total deal value in 2025 Seller/Buyer Date Upfront cash and equity Total deal value Deal Summary Intra-Cellular Therapies; Johnson& Johnson January 2025 $14,600 million $14,600 million 强生公司正在收购 Intra-Cellular Therapies 公司。Intra-Cellular 公司的资产包括 Caplyta，用于治疗精神分裂症等，以及用于治疗帕金森病和心力衰竭的 2 期药物 lenrispodun，用于治疗焦虑和精神病的氘代 lumateperone、用于治疗癌症的 ITI-1020 和用于治疗疼痛的 ITI-333。 Verona Pharma; Merck & Co July 2025 $10,000 million $10,000 million 默克公司正在收购 Verona Pharma 及其主要资产 Ohtuvayre（ensifentrine），一种选择性双重磷酸二酯酶 3 和 4（PDE3 和 PDE4）抑制剂，用于治疗成人 COPD。 Blueprint Medicines; Sanofi June 2025 $9,100 million $9,500 million 赛诺菲正在收购 Blueprint Medicines 及其资产，包括用于治疗胃肠道间质瘤的 ayvakit、用于治疗系统性肥大细胞增生症的 3 期药物 elenestinib 和用于治疗荨麻疹的 2 期药物 BLU-808。 Endo International; Mallinckrodt March 2025 $80 million $6,700 million Mallinckrodt 正在以股票和现金交易方式收购 Endo。Endo 的资产包括 27 种已批准产品，包括用于治疗性腺功能减退症的 Aveed、用于治疗偏头痛的 Frova 和用于治疗贫血的 Nascobal。 SpringWorks Therapeutics; Merck KGaA April 2025 $3,500 million $3,500 million 默克 KGaA 正在收购 Spring Works Therapeutics。Spring Works 的主要资产包括已获批准的 Ogsiveo（nirogacestat），用于治疗成人硬纤维瘤，目前还在 2 期试验中研究用于治疗儿童硬纤维瘤的药物，以及用于治疗神经纤维瘤的 Gomekli（mirdametinib）。 Mitsubishi Tanabe Pharma Corporation; Bain Capital February 2025 $3,300 million $3,300 million 贝恩资本正在收购三菱田边制药及其资产；用于治疗视神经脊髓炎谱系障碍的 Uplizna、用于治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 Zynlonta、用于治疗糖尿病的 Canalia、用于治疗继发性甲状旁腺功能亢进症的 Orkedia 和用于治疗糖尿病肾病的 Invokana。 Anthos Therapeutics; Novartis February 2025 $925 million $3,075 million 诺华正在收购 Anthos Therapeutics 及其 3 期资产 abelacimab，这是一种靶向 FXI 抑制途径的单克隆抗体，用于治疗房颤和静脉血栓栓塞，以及用于治疗卒中和血栓形成的 2 期药物。Anthos 于 2019 年从诺华获得了 abelacimab 的许可。 Scorpion Therapeutics; Eli Lilly and Co. January 2025 $2,500 million $2,500 million 礼来正在收购 Scorpion Therapeutics，包括其 1/2 期、每日一次的口服 PI3Kα 抑制剂项目、用于治疗乳腺癌和其他晚期实体瘤的 STX-478。此次收购加强了礼来在乳腺癌方面的专业知识，并且仅包括 PI3Kα 抑制剂项目。 Capstan Therapeutic; AbbVie June 2025 $2,100 million $2,100 million 艾伯维正在收购 Capstan。Capstan 的资产包括 1 期药物 CPTX-2309，一种体内 tLNP 抗 CD19 CAR-T 疗法，用于治疗 B 细胞介导的自身免疫性疾病、CAR-T 疗法 CPTX-2506 以及其靶向脂质纳米颗粒平台，旨在递送 RNA。 Regulus Therapeutics; Novartis April 2025 $800 million $1,700 million 诺华正在收购 Regulus Therapeutics 及其用于治疗常染色体显性多囊肾病的 1b 期药物 farabursen。该交易还包括其他资产以及肾脏病学和中枢神经系统疾病的研究项目。 Top 10 biopharma R&D licensing partnerships ranked by total deal value in 2025 Out-licensor; in-licensee Date Upfront payment Total deal value Deal summary Jiangsu Hengrui Pharmaceuticals; GSK July 2025 $500 million $12,500 million 恒瑞医药授予GSK在除中国大陆、香港、澳门和台湾以外的全球范围内独家开发与商业化HRS-9821的权利。HRS-9821是一种目前正处于临床开发阶段的PDE3/4抑制剂，用于治疗慢性阻塞性肺病（COPD）。GSK可将其开发为便捷的干粉吸入剂。此外，恒瑞还将继续推进另外11个早期项目至I期临床阶段。 BioNTech SE; Bristol Myers Squibb (BMS) June 2025 $1,500 million $11,100 million BioNTech授予BMS在全球范围内独家开发与商业化BNT-327的权利，这是一种靶向PD-L1和VEGF-A的双特异性抗体，用于治疗多种实体瘤。BNT-327目前正在超过20项癌症相关研究中进行评估，包括小细胞肺癌和非小细胞肺癌的全球III期注册临床试验，并计划于2025年底前启动三阴性乳腺癌的III期试验。BioNTech通过收购Biotheus获得该资产，并将为正在进行的试验提供药物。 3SBio; Pfizer May 2025 $1,350 million $6,300 million 沈阳三生制药及其全资子公司上海三生国健授予辉瑞在除中国以外的全球范围内独家开发、生产与商业化SSGJ-707的权利。这是一种靶向PD-1和VEGF的双特异性抗体，用于治疗非小细胞肺癌（NSCLC）、转移性结直肠癌及妇科肿瘤。辉瑞有权选择在中国商业化SSGJ-707，并可在其位于北卡罗来纳州桑福德和堪萨斯州麦克弗森的工厂分别生产原料药和制剂。三生制药将于2025年在中国启动首个III期临床试验。 CSPC Pharmaceutical Group; AstraZeneca June 2025 $110 million $5,330 million 阿斯利康与石药集团签署了一项研究合作协议，共同开发多个口服候选药物，包括一种用于免疫疾病的临床前口服小分子药物及其他多种慢性病药物。石药集团将在石家庄进行研究，并利用其AI驱动的双引擎高效药物发现平台。阿斯利康拥有独家选择权以授权引进该项目。 Zealand Pharma; Roche March 2025 $1,650 million $5,250 million 西兰制药授予罗氏在全球范围内共同开发与商业化petrelintide的独家权利。petrelintide是一种用于肥胖症治疗的胰淀素类似物，既可单独使用，也可与罗氏的双重GLP-1/GIP受体激动剂CT-388联合使用。该合作将petrelintide整合至罗氏的心血管、肾脏与代谢（CVRM）产品管线中，与其药物及诊断产品组合形成协同效应。 Harbour BioMed (HBM); AstraZeneca March 2025 $280 million $4,680 million 和铂医药与阿斯利康签署了一项研究合作，利用和铂医药的Harbour Mice全人源抗体技术开发用于免疫、癌症及其他疾病治疗的抗体。阿斯利康拥有全球范围内的选择权，可开发与商业化两种临床前免疫抗体，并将在后续提名更多靶点。双方还可选择增加更多靶点，并将协议期限延长五年。和铂医药将在北京设立一个与阿斯利康同址的研究中心。 Orna Therapeutics; Vertex Pharmaceutical; ReNAgade Therapeutics January 2025 $65 million $4,350 million Orna通过其全资子公司ReNAgade授予Vertex在三年内开发与商业化多个未公开的基因编辑疗法的权利，用于治疗镰状细胞病（SCD）和输血依赖性β地中海贫血（TDT），并将利用Orna的脂质纳米颗粒（LNP）递送系统增强靶向造血干细胞（HSC）的基因疗法。Vertex可选择延长合作，并最多增加10个新靶点。 RemeGen; Vor Bio June 2025 $125 million $4,125 million 荣昌生物授予Vor Bio在除中国大陆、香港、澳门和台湾以外的全球范围内独家开发与商业化泰它西普（telitacicept）的权利。这是一种靶向BlyS（BAFF）和APRIL的双靶点融合蛋白，用于治疗全身型重症肌无力。该药在中国已获批用于全身型重症肌无力（gMG）、系统性红斑狼疮（SLE）和类风湿关节炎（RA），其全球III期临床试验正在推进中。 Syneron Bio; AstraZeneca March 2025 $75 million $3,475 million Syneron Bio授予阿斯利康开发与商业化大环肽的权利，这些肽类基于Syneron Bio的Synova平台开发，用于治疗包括罕见病、自身免疫疾病和代谢疾病在内的慢性病。 ABL Bio; GSK April 2025 $50 million $2,724 million ABL Bio授予GSK在全球范围内独家开发、生产与商业化抗体、多核苷酸或寡核苷酸（如siRNA和ASO）的权利，用于治疗神经系统疾病。该合作将利用ABL的Grabody-B血脑屏障（BBB）穿越平台及其专有技术。注：以上数据截至2025年7月29日，来源为DealForms 2025。空白财务信息未提供，所有信息归DealForms所有。 JPM 2025年第四季度生物制药许可与风险投资报告 2025年第四季度生物制药风险投资总额为70亿美元，与2024年同期持平。继2024年行业复苏后的初期势头，到第二季度就已消退，直到年底才重新回升。风险投资更青睐那些拥有具备近期临床及商业化潜力的先进治疗管线的公司。 2025年生物制药风险投资以中性基调收尾 2025年完成风险融资的公司数量有所减少，但成功融资的公司愈发集中于后期阶段，且融资规模更大。全年共有80轮风险融资超过1亿美元，这凸显了投资者更倾向于选择那些规模更大、价值拐点路径更清晰的机遇。与此同时，授权交易带来的首付款也大幅提高。在风险投资有限的情况下，大型生物制药公司为了获取先进或具有战略关键性的资产，共达成了41项首付款超过1亿美元的授权协议。 2025年，价值创造的重心从风险融资轮次转向了授权交易首付款截至2025年第四季度，种子轮和A轮融资速度放缓，失去了今年早些时候积累的势头，并进一步落后于B轮及以后轮次。早期阶段融资的放缓反映出投资者对初创公司的尽职调查标准更加严格，决策周期也更长。后期轮次继续在风险投资活动中占据主导地位，因为投资者优先考虑那些拥有已确立的临床数据和风险已被降低的开发路径的项目。这种态势加剧了行业内不同阶段公司之间的资本鸿沟。早期风险投资活动减弱，与后期阶段的差距进一步拉大 2025年，处于II期临床阶段的公司其风险融资中位数增至6000万美元，延续了多年的增长趋势。这一变化反映出投资者更青睐那些具有已验证机制、更明确终点指标和技术风险较低的资产。处于III期临床阶段及更后期阶段的公司则维持了较高的融资水平，资本持续流向那些即将进入注册或商业化阶段的项目。而早期公司从这一趋势中获益较少，使得融资环境的分化进一步加剧。处于II期临床阶段及更后期阶段的公司，其风险融资中位数均有所上升截至2025年第四季度，生物制药领域已公布的许可交易总额攀升至516笔交易的2502亿美元，为2016年以来的最高水平。首付款占交易总额的比例保持稳定，为7%，与近年来持平。交易总额的增长主要得益于扩大的里程碑付款组合，其中包含多资产和基于平台的协议。这种结构使许可方能够获得近期资本，同时保留其成功开发和商业化成果的上升参与权。许可交易总额创下多年新高，得益于里程碑付款结构的推动生物药，特别是抗体药物偶联物（ADC），在2025年的种子轮和A轮风险融资以及授权交易首付款中均占据主导地位。以ADC为重点的大型交易在合作投入的 upfront cash 中占据了显著份额。小分子药物仍是第二大活跃的药物类型，这得益于其较低的开发成本和成熟的监管路径。虽然生物药在绝对金额上占比最大，但小分子药物在风险投资和授权交易渠道中持续吸引着稳定的投资。基因疗法重燃的兴趣为2025年带来了早期风险融资和授权交易首付款。 ADC生物制剂在早期风险融资和授权交易首付款中均占据主导地位 2025年，大型生物制药公司依然聚焦于后期授权引进，为III期资产支付了显著更高的首付款。它们也为临床前资产支付了更高的费用，以抢占上游机会。I期和II期项目的首付款中位数则较2024年水平有所下降。更早期的交易使授权引进方能够在承担开发风险的同时获得战略选择权，这在竞争激烈的治疗领域尤为突出。临床前阶段交易策略的这种转变，凸显了高质量后期资产的稀缺性以及为早期介入所支付的溢价。在专利即将到期的情况下，大型制药公司为临近上市的资产支付了更高的首付款肿瘤领域依然是大型生物制药公司授权交易中最活跃的治疗领域。从2024年到2025年，处于II期临床阶段的肿瘤项目，其首付款中位数约为1.5亿美元，而III期资产的首付款则超过了10亿美元。对于后期资产，其里程碑付款组合显著扩大，针对III期项目，基于批准和销售的数十亿美元里程碑付款已成为常态。这种经济回报反映了市场对具有近期商业影响力的差异化肿瘤资产的持续需求。肿瘤学领域的许可条款更倾向于具有巨大潜力的后期资产生物制剂在2025年仍是已公布的研发合作总价值中最大的贡献者，其中以ADC为主导的交易推动了几项重磅交易，并维持了季度总额的高位。这种药物类型的构成反映出赞助方持续倾向于那些具有明确差异化和强大临床定位的项目，尤其是在肿瘤领域。小分子在已公布交易总价值中排名第二，并在2025年实现了显著增长，其中包括第三季度的强劲贡献。在这两种药物类型中，庞大的里程碑付款结构继续支撑着交易总额，而最大的交易则集中在高竞争性资产和经过充分验证的靶点上。 2025年，生物制剂和小分子继续主导许可交易价值截至2025年第四季度，肥胖和糖尿病领域的研发合作加速推进，创下了创纪录的交易总额和首付款。尽管交易数量减少，但累计产生的总价值却显著高于往年，凸显了各方在代谢疾病领域日益增强的战略聚焦。靶向GLP-1、GLP-1R和GIP的项目占据了重磅交易价值的显著份额，其中多笔交易涉及九位数的首付款。这一趋势反映出大型赞助方之间强烈的商业验证和竞争定位。 2025年，肥胖和糖尿病领域的交易活动达到创纪录水平全球大型生物制药公司持续从中国生物医药企业引进资产，其中首付款超过5000万美元的交易占比不断提高。截至2025年，中国在全球大型药企的授权交易支出中占据了可观份额。这一趋势既反映了中国创新生态系统的日益成熟，也体现了跨国赞助方对差异化临床项目和成本效益开发能力的持续关注。中国生物制药公司仍然是大型授权交易活动的重要来源 2025年生物制药并购活动的已公布总价值超过了2024年，这一增长由数笔数十亿美元级别的交易驱动。从交易数量来看，中小型公司占据了大部分份额，收购方瞄准的是价值被低估的上市和非上市资产。值得注意的2025年第四季度生物制药公司之间的收购公告包括：诺华收购Avidity Biosciences（120亿美元）、默克收购Cidara Therapeutics（92亿美元），以及诺和诺德收购Akero Therapeutics（52亿美元）。尽管面临估值压力，2025年生物制药并购总金额仍超过2024年 2025年第四季度，IPO活动依然低迷，仅有9家生物制药公司在美国交易所上市。募资总额处于十多年来的最低水平之一，反映出投资者持续的谨慎态度。那些成功上市的公司通常是处于后期阶段且规模适中的企业，这凸显了早期发行公司面临的持续挑战。相对于并购和许可交易，IPO市场仍然是一条次要的退出途径。 2025年，生物制药IPO的窗口依然紧闭参考资料： [1]. Biopharma deal watch in 2025. A review of the first half of the year’s highest value partnerships, including mergers and acquisitions with the help of DealForma. [2]. Q4 2025 Biopharma Licensing and Venture Report. [3]. Mega M&A amid JPM 2025 signals potential biopharmaceutical M&A rebound, says GlobalData.

并购临床2期临床3期引进/卖出

100 项与甲苯磺酸卢美哌隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11170	甲苯磺酸卢美哌隆	N05A	DB06077

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	美国	Johnson & Johnson	2025-11-07
重度抑郁症	美国	Intra-Cellular Therapies, Inc.	2025-11-05
躁郁症	美国	Intra-Cellular Therapies, Inc.	2021-12-17
精神分裂症	美国	Intra-Cellular Therapies, Inc.	2019-12-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
情绪易怒	临床3期	美国	Intra-Cellular Therapies, Inc.	2024-11-22
躁郁症1型	临床3期	美国	Intra-Cellular Therapies, Inc.	2024-06-19
躁郁症1型	临床3期	保加利亚	Intra-Cellular Therapies, Inc.	2024-06-19
躁郁症1型	临床3期	克罗地亚	Intra-Cellular Therapies, Inc.	2024-06-19
躁郁症1型	临床3期	印度	Intra-Cellular Therapies, Inc.	2024-06-19
躁郁症1型	临床3期	塞尔维亚	Intra-Cellular Therapies, Inc.	2024-06-19
躁狂	临床3期	美国	Intra-Cellular Therapies, Inc.	2024-06-19
躁狂	临床3期	保加利亚	Intra-Cellular Therapies, Inc.	2024-06-19
躁狂	临床3期	克罗地亚	Intra-Cellular Therapies, Inc.	2024-06-19
躁狂	临床3期	印度	Intra-Cellular Therapies, Inc.	2024-06-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04779177 (CTgov)	临床1期	分裂情感性障碍 \| 精神分裂症	26	Lumateperone 42 mg	淵艱糧齋鹽齋衊醖鏇積(壓鏇廠窪餘膚鹽鏇選鏇) = 鹹鏇齋鑰鬱襯鹽積鏇窪糧壓膚襯繭簾選顧網廠 (願糧簾鹽憲製糧簾衊範, 11.21) 更多	-	2025-11-12
NCT02600494 (CTgov)	临床3期	躁郁症 \| 躁郁症2型 \| 重度抑郁症	554	Placebo	遞範構簾簾願糧鹽鏇鑰(獵願壓窪鹽獵淵憲網網) = 窪製觸夢艱衊壓鏇襯築窪襯夢窪繭築淵醖觸網 (夢艱構憲糧鹽衊鬱範顧, 1.11) 更多	-	2025-11-03
NCT05061719 (CTgov)	临床3期	重度抑郁症	812	Lumateperone	鏇範鑰顧襯壓憲築網築 = 網築憲鹽願繭窪齋餘糧壓築餘壓繭糧獵積簾淵 (醖襯醖夢鹹艱醖廠鏇膚, 鏇襯鑰構夢鑰製夢鹹遞 ~ 襯鏇簾蓋廠窪顧網齋繭) 更多	-	2025-11-03
NCT01499563 (CTgov)	临床2期	精神分裂症	335	Placebo	遞構窪構積築窪鬱壓鑰(遞簾積糧鬱壓構選憲築) = 夢簾繭窪廠襯壓壓鏇網選願膚鬱壓膚遞鑰窪廠 (積醖鹽餘簾蓋夢鬱憲窪, 1.7) 更多	-	2025-10-03
NCT02469155 (CTgov)	临床3期	精神分裂症	696	ITI-007 (Lumateperone 14 mg (ITI-007 20 mg Tosylate))	繭衊獵衊簾窪蓋構憲鏇(夢糧壓範獵鹹簾網夢簾) = 糧糧餘鹽蓋繭鑰選簾鬱製窪顧繭築齋鏇醖鹹願 (網觸選鏇壓遞齋蓋壓繭, 1.27) 更多	-	2025-10-02
				ITI-007 (Lumateperone 42 mg (ITI-007 60 mg Tosylate))	繭衊獵衊簾窪蓋構憲鏇(夢糧壓範獵鹹簾網夢簾) = 憲衊鏇遞廠鹽範淵憲獵製窪顧繭築齋鏇醖鹹願 (網觸選鏇壓遞齋蓋壓繭, 1.23) 更多
NCT02282761 (CTgov)	临床3期	精神分裂症	450	ITI-007 (Lumateperone 28 mg (ITI-007 40 mg Tosylate))	壓遞繭鏇築蓋築壓積淵(鹹網壓齋簾簾鹹夢觸餘) = 艱鏇夢鏇淵餘築選壓鑰襯鬱醖糧廠鹹鏇獵膚齋 (襯網齋觸顧壓鬱鏇選艱, 1.27) 更多	-	2025-10-02
				ITI-007 (Lumateperone 42 mg (ITI-007 60 mg Tosylate))	壓遞繭鏇築蓋築壓積淵(鹹網壓齋簾簾鹹夢觸餘) = 網廠願範製衊觸選選構襯鬱醖糧廠鹹鏇獵膚齋 (襯網齋觸顧壓鬱鏇選艱, 1.25) 更多
NCT04985942 (CTgov)	临床3期	重度抑郁症	485	Lumateperone (Lumateperone 42 mg)	淵製餘鑰夢蓋艱齋蓋構(窪觸築鬱襯憲衊積繭觸) = 蓋餘構簾遞遞襯顧醖鬱艱鏇壓鹽夢蓋壓繭鹽鏇 (艱餘蓋築夢糧衊窪蓋積, 0.54) 更多	-	2025-05-02
				Placebo (Placebo)	淵製餘鑰夢蓋艱齋蓋構(窪觸築鬱襯憲衊積繭觸) = 願糧蓋鏇鬱齋選夢鏇遞艱鏇壓鹽夢蓋壓繭鹽鏇 (艱餘蓋築夢糧衊窪蓋積, 0.53) 更多
NCT05061706 (ITI-007-502, CTgov)	临床3期	重度抑郁症	480	Lumateperone (Lumateperone 42 mg)	艱襯憲網艱繭淵選艱選(製鹽築齋繭網鬱蓋壓築) = 鹽襯鑰鑰艱壓蓋繭艱遞衊範網廠鹹衊簾遞襯構 (廠觸鬱鬱鹹鹽鏇選壓選, 0.56) 更多	-	2025-03-25
				Placebo (Placebo)	艱襯憲網艱繭淵選艱選(製鹽築齋繭網鬱蓋壓築) = 構製餘遞餘築壓襯願糧衊範網廠鹹衊簾遞襯構 (廠觸鬱鬱鹹鹽鏇選壓選, 0.54) 更多
NCT04285515 (CTgov)	临床3期	躁郁症 \| 躁郁症2型 \| 重度抑郁症	488	Lumateperone (Lumateperone 42mg)	鏇鬱鹽獵衊衊淵鹽遞艱(壓遞獵糧網願鏇壓鑰淵) = 選顧顧餘膚範鹹廠壓積窪鬱窪繭願鬱淵餘蓋糧 (選鏇選鬱願觸艱憲憲鏇, 0.71) 更多	-	2025-03-19
				Placebos (Placebo)	鏇鬱鹽獵衊衊淵鹽遞艱(壓遞獵糧網願鏇壓鑰淵) = 築選積衊觸鏇衊鏇製築窪鬱窪繭願鬱淵餘蓋糧 (選鏇選鬱願觸艱憲憲鏇, 0.70) 更多
NCT04959032 (Company_Website) 人工标引	临床3期	精神分裂症	228	Lumateperone 42 mg	選獵觸醖遞壓構鹽鏇範(鏇網鹹鑰繭糧艱壓糧襯) = 壓糧構鑰壓夢鹹壓網鑰觸獵鬱餘鹽醖衊選簾鬱 (齋鏇鏇糧觸鏇醖鹽壓選 ) 达到	积极	2024-11-05
				Placebo	選獵觸醖遞壓構鹽鏇範(鏇網鹹鑰繭糧艱壓糧襯) = 簾襯醖壓蓋淵憲鹽鹹觸觸獵鬱餘鹽醖衊選簾鬱 (齋鏇鏇糧觸鏇醖鹽壓選 ) 达到